Mission Statement, Vision, & Core Values (2026) of China Resources Boya Bio-pharmaceutical Group Co., Ltd.

Discover how China Resources Boya Bio-pharmaceutical Group Co., Ltd. is translating a focused mission into measurable progress - from a 1993 founding into a biopharma leader reporting ¥2.759 billion in revenue and ¥432 million in net profit in 2022 (up 4.08% and 25.45% year-on-year respectively), operating 14 plasma collection stations with plans to exceed 30 during the 14th Five-Year Plan, and committing roughly 10% of annual revenue to R&D to drive innovations like the May 2025 approval to begin clinical trials for subcutaneous immunoglobulin; the company's vision - backed by a 98% compliance rate with national quality standards in 2023, strategic partnerships with over 10 industry and academic collaborators, a goal to enter five new countries in 2024, a 15% waste reduction achieved in 2023, and an ambitious target to cut carbon emissions by 40% by 2030 - is reinforced by core values of Integrity, Innovation, Harmony, Development, Sustainability and Quality as CR Boya builds a smart factory to elevate blood-product standards and expand global reach.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Intro

• Core businesses: plasma-derived blood products, recombinant coagulation factors, immunoglobulin formulations, albumin, biochemical and chemical therapeutics, APIs.
• Geographic footprint: 14 plasma collection stations (current) with a target of expanding to over 30 during the 14th Five-Year Plan (2021-2025).
• Recent regulatory milestone: May 2025 approval to initiate a clinical trial for subcutaneous immunoglobulin, positioning the company for broader market access and improved patient convenience.

• Deliver safe, effective blood-derived therapeutics and high-quality pharmaceuticals that improve patient outcomes across China and select international markets.
• Ensure plasma sourcing integrity and product safety through advanced collection standards and traceability.

• Become a benchmark biopharmaceutical enterprise in China for blood products and biologics, driven by innovation, digitalized manufacturing, and scalable plasma supply.

• Patient-first safety: uncompromising standards in donor screening, fractionation, and product quality control.
• Scientific rigor: robust R&D investment in recombinant and subcutaneous formulations to expand therapeutic options.
• Operational excellence: smart manufacturing and supply-chain resilience to meet clinical demand reliably.
• Compliance and ethics: adherence to regulatory requirements and traceability across the plasma-to-product lifecycle.

• Scale plasma collection network from 14 stations to >30 by 2025 to secure raw material supply and reduce regional concentration risk.
• Complete construction and commissioning of a smart factory for blood products to raise industry standards, increase capacity, and enable digital QC/automation.
• Advance clinical pipeline-accelerate development of subcutaneous immunoglobulin and optimize commercial pathways for immunoglobulin, coagulation factors, and albumin.

• 2022 financial performance: revenue ¥2.759 billion (+4.08% YoY); net profit ¥432 million (+25.45% YoY), reflecting margin expansion and operational leverage.
• Manufacturing scale: ongoing smart factory project designed to increase batch throughput, reduce per-unit costs, and support new product registrations.
• R&D and regulatory: May 2025 clinical trial approval for subcutaneous immunoglobulin opens a high-potential route for home-based therapy and differentiated pricing.

• Plasma-derived immunoglobulins: expand indications and delivery routes (IV to subcutaneous).
• Coagulation factors: maintain leadership in hemophilia therapies via both plasma-derived and recombinant approaches.
• APIs and chemical-biological integration: leverage verticalization to control cost and supply security.

• Financial momentum: 2022 net profit growth of 25.45% signals improving profitability despite modest revenue growth (4.08%).
• Capacity and supply investments: expansion of plasma stations and smart factory convey management's focus on securing raw materials and industrializing quality.
• Regulatory wins: clinical trial approval (May 2025) for subcutaneous immunoglobulin is a de-risking step toward a high-value product launch.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Overview

• Mission statement: committed to advancing human health by delivering effective healthcare solutions through innovative research and product development.
• R&D commitment: allocates approximately 10% of annual revenue to research and development, reflecting sustained investment in pipeline growth and technology platforms.
• Sustainability target: aims to reduce carbon emissions by 40% by 2030 as part of an integrated environmental management plan.
• Plasma and blood products: emphasizes comprehensive utilization of plasma to enhance efficiency and effectiveness across its portfolio of blood-derived therapies and plasma derivatives.
• Partnerships: strategic co-development agreements with leading pharmaceutical firms and academic institutions to accelerate cutting‑edge therapies from discovery to commercialization.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Mission Statement

• Vision: Become a leader in biotechnology via innovative research and product development, delivering safe, effective therapies worldwide.
• Quality & Safety: Achieved a 98% compliance rate with national quality standards in 2023, reflecting robust QA/QC systems across manufacturing and clinical processes.
• Global Expansion: Targeting entry into five new countries in 2024 to broaden market reach and streamline international regulatory pathways.
• Collaboration: Established strategic partnerships with more than 10 leading pharmaceutical firms and academic institutions as of 2024 to accelerate translational research and commercialization.
• Sustainability: Implemented waste reduction strategies that yielded a 15% reduction in waste generated during 2023.

• Core values: Scientific excellence, patient‑centricity, compliance and transparency, collaborative innovation, environmental responsibility.
• Strategic priorities: Scale R&D pipelines, enhance GMP and regulatory capabilities, execute targeted international market entries, deepen industry and academic alliances, and continue measurable sustainability initiatives.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Vision Statement

• Integrity: Emphasizing honesty to customers, loyalty to the enterprise, and enthusiasm to colleagues as guiding behavioral norms.
• Innovation: Treating innovation as the soul of operations to drive continuous improvement in R&D, manufacturing, and service delivery.
• Harmony: Promoting cooperation and win-win relationships across the value chain to foster a collaborative operating environment.
• Development: Committing to ongoing growth as the essential route to realizing the company's strategic vision and mission.
• Sustainability: Targeting a 40% reduction in carbon emissions by 2030 as part of enterprise-wide environmental stewardship.
• Quality: Maintaining rigorous quality and safety controls, achieving a 98% compliance rate with national quality standards in 2023.

• R&D orientation - directing resources to novel therapeutics and process innovation to sustain product pipeline and competitiveness.
• Quality systems - continuous improvement across GMP, QC, and post-market surveillance to sustain the 98% compliance achievement.
• Green transformation - energy efficiency, process optimization, and supply-chain decarbonization to meet the -40% emissions goal by 2030.
• Partnerships - collaborative models with hospitals, research institutions, and industry partners to reinforce harmony and shared value creation.